Business, energy, technology, markets and global industry news from Business News Today

The Menopause Society

PharmaDeviceNews The Menopause Society
AbCellera’s ABCL635 Phase 2 trial is testing whether a long-acting neurokinin 3 receptor antibody can reduce moderate-to-severe menopause hot flashes and support a less frequent dosing approach. Representative image.
Pharma & Biotech

AbCellera’s ABCL635 cut hot flashes by 83%. Can the biotech turn Phase 2 success into a viable drug?

AbCellera heads to UBS after positive ABCL635 Phase 2 results and a $200 million financing. Examine its clinical and commercial priorities.

Read More
A woman experiencing menopause-related fatigue and discomfort, as Bonerge Lifescience launches a clinical study evaluating EquoYouth S-equol for potential menopause symptom relief. Representative image.
Pharma & Biotech

Bayer’s LYNKUET cut poor sleep reports sharply, but does that make it a menopause sleep treatment?

Bayer's LYNKUET showed improved self-reported sleep quality in a post-hoc Phase 3 analysis. The findings do not establish a separate sleep indication.

Read More
Editorial infographic highlighting AbCellera’s ABCL635 programme, featuring an antibody graphic, laboratory visuals and symptom-tracking charts, with key points on an 83% reduction in hot flashes, upcoming safety results, new symptom data and the open question of durability.
Pharma & Biotech

One ABCL635 injection cut hot flashes by 83%. Can AbCellera prove the benefit lasts?

AbCellera will reveal new ABCL635 safety and symptom data after reporting an 83% hot flash reduction. Can its antibody sustain the benefit?

Read More
A woman experiencing menopause-related fatigue and discomfort, as Bonerge Lifescience launches a clinical study evaluating EquoYouth S-equol for potential menopause symptom relief. Representative image.
Pharma & Biotech

Can Bonerge’s EquoYouth S-equol study strengthen evidence for menopause relief?

Bonerge Lifescience begins an EquoYouth S-equol menopause study as researchers test whether new data can strengthen a contested supplement case.

Read More